Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 70 of 70 matching drugs for BLK — including drugs targeting any of its 22 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
dasatinib BLK Direct yes 0
vandetanib BLK Direct yes 0
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FRK SSL via FRK 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FRK SSL via FRK 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FRK SSL via FRK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LYN SSL via LYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FRK SSL via FRK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LYN SSL via LYN 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
nintedanib LYN SSL via LYN 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab LYN SSL via LYN 2
nintedanib, pembrolizumab SRC SSL via SRC 2
pazopanib SH2B3 SSL via SH2B3 2
regorafenib FRK SSL via FRK yes 2
regorafenib, laboratory biomarker analysis FRK SSL via FRK 2
afatinib, dasatinib, palbociclib, everolimus, olaparib FRK SSL via FRK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib LYN SSL via LYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
bevacizumab, dasatinib, placebo FRK SSL via FRK 1
bevacizumab, dasatinib, placebo LYN SSL via LYN 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
bosutinib LYN SSL via LYN 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LYN SSL via LYN 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FRK SSL via FRK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LYN SSL via LYN 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FRK SSL via FRK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LYN SSL via LYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing FRK SSL via FRK 1
dasatinib, laboratory biomarker analysis, physiologic testing LYN SSL via LYN 1
dasatinib, laboratory biomarker analysis, physiologic testing SRC SSL via SRC 1
dasatinib, mfolfox6 FRK SSL via FRK 1
dasatinib, mfolfox6 LYN SSL via LYN 1
dasatinib, mfolfox6 SRC SSL via SRC 1
dasatinib, pharmacological study FRK SSL via FRK 1
dasatinib, pharmacological study LYN SSL via LYN 1
dasatinib, pharmacological study SRC SSL via SRC 1
dasatinib, temozolomide, placebo, radiation therapy FRK SSL via FRK 1
dasatinib, temozolomide, placebo, radiation therapy LYN SSL via LYN 1
dasatinib, temozolomide, placebo, radiation therapy SRC SSL via SRC 1
pazopanib, 5-fu, oxaliplatin, leukovorin (flo) SH2B3 SSL via SH2B3 1
pazopanib, lapatinib SH2B3 SSL via SH2B3 1
pazopanib, placebo SH2B3 SSL via SH2B3 1
pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin SH2B3 SSL via SH2B3 1
ponatinib LYN SSL via LYN 1
ponatinib SRC SSL via SRC 1
regorafenib, lomustine FRK SSL via FRK 1
regorafenib, nivolumab, capeox, folfox regimen FRK SSL via FRK 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil FRK SSL via FRK 1
regorafenib, temozolomide FRK SSL via FRK 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 FRK SSL via FRK 1
topotecan, pazopanib SH2B3 SSL via SH2B3 1
dasatinib FRK SSL via FRK yes 0
dasatinib LYN SSL via LYN yes 0
dasatinib SRC SSL via SRC yes 0
dasatinib SRMS SSL via SRMS yes 0
tirbanibulin SRC SSL via SRC yes 0
vandetanib FRK SSL via FRK yes 0
vandetanib LYN SSL via LYN yes 0
vandetanib SRC SSL via SRC yes 0
vandetanib SRMS SSL via SRMS yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.